More recently, in 2024, the FDA granted approval for vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, for the treatment of adult and pediatric patients aged 12 and older with grade-2 astrocytoma or oligodendroglioma following surgery (including biopsy, subtotal resection, or gross total resection) and with a susceptible IDH1 or IDH2 mutation [16]. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).